Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Last trade$0.6301
Day change+$0.0601 (+10.54%)
Day range$0.55 – $0.675
Volume181,956
Market cap$10M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$10.23M
Price / earnings
—
Price / book
-42.1×
Price / sales
0.21×
EV / sales
0.24×
EV / EBITDA
-1.8×
Profitability
Earnings per share
-$0.34
Return on assets
-28.6%
Return on equity
2,526.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-19.54×
Current ratio
0.78×
Quick ratio
0.66×
Cash ratio
0.23×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$5.55M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BFRI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9.07M
$12M
$10.08M
$17.1M
$6.99M
$9.03M
$8.59M
$12.56M
Cost of revenue
$2.32M
$2.41M
$2.12M
$3.01M
$2.05M
$2.64M
$3.27M
$5.27M
Gross profit
$6.75M
$9.59M
$7.97M
$14.09M
$4.94M
$6.39M
$5.32M
$7.29M
Selling, general and administrative
$12.49M
$9.67M
$11M
$8.75M
$10.37M
$10.6M
$8.66M
$8.22M
Research and development
$450K
$448K
$900K
$787K
$854K
$870K
$1.21M
$783K
Total operating expenses
$13.25M
$10.12M
$12.29M
$9.53M
$11.22M
$11.47M
$9.87M
$9M
Operating income
-$6.5M
-$524K
-$4.32M
$4.56M
-$6.28M
-$5.08M
-$4.55M
-$1.71M
Interest expense
-$128K
-$126K
-$125K
$331K
-$111K
-$115K
-$106K
$2M
Income before taxes
-$6.42M
-$581K
-$4.75M
$5.64M
-$6.64M
-$5.3M
-$4.2M
-$1.4M
Income taxes
$4K
$23K
$0
$0
$6K
$21K
-$1K
-$3K
Net income
-$6.42M
-$604K
-$4.75M
$5.64M
-$6.65M
-$5.32M
-$4.2M
-$1.4M
Net income attributable to common shareholders
-$6.42M
-$604K
-$4.75M
$5.64M
-$6.65M
-$5.32M
-$4.2M
-$1.4M
EBITDA
-$6.44M
-$459K
-$4.27M
$4.62M
-$6.26M
-$5.05M
-$4.52M
-$1.68M
Basic earnings per share
-$0.42
-$0.05
-$0.41
$0.48
-$0.62
-$0.57
-$0.47
-$0.18
Diluted earnings per share
-$0.42
-$0.05
-$0.41
$0.48
-$0.62
-$0.57
-$0.47
-$0.18
Recent news
Company coverage with links to the original publishers.
Biofrontera Inc. (NASDAQ: BFRI) announced it will report third quarter 2026 financial results on November 13, 2026, followed by a management conference call. The company, a biopharmaceutical firm focused on dermatological treatments using photodynamic therapy, recently received FDA approval in September 2026 for Ameluz® Red Light PDT to treat superficial basal cell carcinoma, marking the first and only photodynamic therapy approved in the U.S. for skin cancer treatment.
MannKind (MNKD) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.08 loss by 12.5%, with revenues of $101.87 million missing estimates by 3.5%. The stock has declined 30.7% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies are under clinical development, with challenges including limited tissue penetration and high system costs.
Biofrontera Inc., a biopharmaceutical company specializing in photodynamic therapy (PDT), announced it will report Q1 2026 financial results on May 14, 2026, followed by a conference call at 11:00 a.m. ET. The company commercializes Ameluz® with RhodoLED® lamp series for treating actinic keratosis and is conducting clinical trials to expand use to non-melanoma skin cancers and acne.
Biofrontera completed its Phase 1 pharmacokinetic study for Ameluz® to expand treatment of actinic keratoses to neck, trunk, and extremities, with plans to submit a supplemental New Drug Application to the FDA in summer 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.